Evidence map›Paper›PMID 35422069›Full record

ArticleNature communications2022

Microvascular stabilization via blood-brain barrier regulation prevents seizure activity.

Chris Greene, Nicole Hanley, Cristina R Reschke, Avril Reddy, Maarja A Mäe, Ruairi Connolly, Claire Behan, Eoin O'Keeffe, Isobel Bolger, Natalie Hudson and 10 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 1 pooled it
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Brain endothelial GαEBioMedicine · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

Chris GreeneSmurfit Institute of Genetics, Trinity College Dublin, Dublin, 2, Ireland.ORCID 0000-0003-4192-9433
Nicole HanleySmurfit Institute of Genetics, Trinity College Dublin, Dublin, 2, Ireland.ORCID 0000-0003-1451-3803
Cristina R ReschkeFutureNeuro, Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland.ORCID 0000-0002-0578-548X
Avril ReddySmurfit Institute of Genetics, Trinity College Dublin, Dublin, 2, Ireland.
Maarja A MäeDepartment of Immunology, Genetics, and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.ORCID 0000-0001-6985-4379
Ruairi ConnollyFutureNeuro, Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland.
Claire BehanFutureNeuro, Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland.
Eoin O'KeeffeSmurfit Institute of Genetics, Trinity College Dublin, Dublin, 2, Ireland.
Isobel BolgerSmurfit Institute of Genetics, Trinity College Dublin, Dublin, 2, Ireland.
Natalie HudsonSmurfit Institute of Genetics, Trinity College Dublin, Dublin, 2, Ireland.
Conor DelaneySmurfit Institute of Genetics, Trinity College Dublin, Dublin, 2, Ireland.ORCID 0000-0001-8735-2225
Michael A FarrellDepartment of Neuropathology, Beaumont Hospital, Dublin, Ireland.
Donncha F O'BrienDepartment of Neurosurgery, Beaumont Hospital, Dublin, Ireland.
Jane CryanDepartment of Neuropathology, Beaumont Hospital, Dublin, Ireland.
Francesca M BrettDepartment of Neuropathology, Beaumont Hospital, Dublin, Ireland.
Alan BeausangDepartment of Neuropathology, Beaumont Hospital, Dublin, Ireland.
Christer BetsholtzDepartment of Immunology, Genetics, and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.
David C HenshallFutureNeuro, Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland.
Colin P DohertyFutureNeuro, Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland.
Matthew CampbellSmurfit Institute of Genetics, Trinity College Dublin, Dublin, 2, Ireland. matthew.campbell@tcd.ie.ORCID 0000-0003-3325-240X
Trinity College Dublin · IERoyal College of Surgeons in Ireland · IEBeaumont Hospital · IEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blood-brain barrier (BBB) dysfunction is associated with worse epilepsy outcomes however the underlying molecular mechanisms of BBB dysfunction remain to be elucidated. Tight junction proteins are important regulators of BBB integrity and in particular, the tight junction protein claudin-5 is the most enriched in brain endothelial cells and regulates size-selectivity at the BBB. Additionally, disruption of claudin-5 expression has been implicated in numerous disorders including schizophrenia, depression and traumatic brain injury, yet its role in epilepsy has not been fully deciphered. Here we report that claudin-5 protein levels are significantly diminished in surgically resected brain tissue from patients with treatment-resistant epilepsy. Concomitantly, dynamic contrast-enhanced MRI in these patients showed widespread BBB disruption. We show that targeted disruption of claudin-5 in the hippocampus or genetic heterozygosity of claudin-5 in mice exacerbates kainic acid-induced seizures and BBB disruption. Additionally, inducible knockdown of claudin-5 in mice leads to spontaneous recurrent seizures, severe neuroinflammation, and mortality. Finally, we identify that RepSox, a regulator of claudin-5 expression, can prevent seizure activity in experimental epilepsy. Altogether, we propose that BBB stabilizing drugs could represent a new generation of agents to prevent seizure activity in epilepsy patients.

Indexed as

Blood-Brain BarrierEndothelial CellsAnimalsClaudin-5HumansMiceSeizuresTight Junction ProteinsTight JunctionsClaudin-5Tight Junction Proteins

Identifiers

PMID35422069
PMCPMC9010415
OpenAlexW4224097781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.